ISSN 3105-6741(Print)
ISSN 3105-675X(Online)
版权信息 · Copyright

     加入编委 / 副主编 / 同行评议专家
ISSN 3105-6741(Print)
ISSN 3105-675X(Online)

CODEN:LYYAA3
国际标准连续出版物标识符·全球唯一标识符
分配机构:美国化学文摘社(CAS)
DOI前缀:
https://doi.org/10.66106/lyyaa3

WorldCat(世界图书馆目录)

OCLC 编号:11198178435

国图集团 CIBTC
进口备案刊号:G015Z125

索引 / 检索 / 存档(Global Indexing)
本刊入选以下全球权威数据库,致力于研究成果的全球化无障碍传播。

CNKI(中国知网,申请中)
CNKI Open(中国知网·开放平台,申请中)
CQVIP(维普期刊网,中国)
CQVIP(中文期刊服务平台,中国)
RCCSE(中国学术期刊目录,武汉大学)
CJWK(长江文库,中国)
BOOKAN(博看,中国)
591adb(中邮阅读·万章期刊,中国)
Baidu Scholar(百度学术,中国)
Baidu Baike(百度百科,中国)
ICI(哥白尼期刊数据库,波兰)
EuroPub(欧洲学术出版数据库,英国)
MDPI scilit(科学与学术数据库,瑞士)
Crossref(交叉引用,美国)
Semantic Scholar(语义学术,美国)
OpenAlex(全球开源学术平台,加拿大)
ACADEMIA.EDU(学术界,美国)
OUCI(开放乌克兰科学,乌克兰)
WorldCat(世界编目数据库,美国)
Scite(智能引文分析数据库,美国)
The Lens(透镜学术,澳大利亚)
OpenAIRE(开放学术发现门户,欧洲)
Google Scholar(谷歌学术,美国)
DOI(数字对象唯一标识符,英国)
Portico(数字存储库,美国)
J-Gate(开放获取期刊门户,印度)
ResearchGate(研究之门,德国)
Research Commons(科睿唯安,美国)
ADL(亚洲数字图书馆,巴基斯坦)
Socolar(开放获取资源检索,中国,更新中)
Sci Online(科学在线,中国澳门)
OALib(开放存取资源图书馆,美国)
EZB(电子期刊图书馆,德国,申请中)
Road(开放科学学术资源,法国)
ISI(国际科学索引平台,阿联酋迪拜)
ASCI(亚洲科学引文索引,美国)
ESJI(欧亚科学期刊索引,哈萨克斯坦)
ResearchBib(研究者索引,日本)
SPI-Hub™(范德比尔特大学,美国)
SJIF(科学期刊影响因子,印度)
RJIF(研究期刊影响因子)
COSMOS(期刊评价指标,印度)
LivRe!(开放期刊门户,巴西)
KIND CONGRESS(阿塞拜疆)
Journament(质量评估与索引)
IP Indexing(ip索引)
Magzter(跨平台数字期刊,美国)
SlideShare(知识共享平台,美国)
SCRIBD(在线图书馆,美国)
Yahoo! Search(雅虎,美国)
Microsoft Bing(微软学术,美国)
LibKey(学术文献快捷获取工具)
R Discovery(研究者发现平台,印度)

Enterscholar(恩特学术,中国)

Scholay(Scholay学术,中国)

Minicod(学术数据 API,法国)

DiscountMags(折扣杂志,美国伊利诺伊)

Rootindexing(根索引,印度)

Synapse(突触,美国)

POSI(全景开放学术索引,中国香港)

GUL(乔治城大学图书馆,美国)

规划申请
Scopus 爱思唯尔·斯高帕斯(荷兰)

SinoMed 中国生物医学文献服务系统

DOAJ 开放获取期刊目录(瑞典)

PubMed 医学文摘数据库(美国)

PubMed Central 医学全文数据(美国)

EMBASE 爱思唯尔·医学文摘(荷兰)

EBSCO 学术文献数据库(美国)

OAJ 全球OA期刊索引(中国)

CABI 国际农业与生物科学中心(英国)

ProQuest 科睿唯安(美国)

Research4Life 世界卫生组织数据库

武汉办事处
主任 库盛娟
电话 +86 027-8860 7188
邮箱 gjqk@qikan999.com
微信 qikan7188
地址 武汉市武昌东湖路181号
邮编 430077
Editing and Publishing
Macau Sino-Foreign Medical Publishing Limited(MSFMP)
Address
Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Telephone
+853 6881 9699
Email
QuestPress@hotmail.com
Web site
https://lcyyyj.scionline2025.com

  往期阅览 · All Issues-> 2026年 · 2026  
临床用药研究,2026年,第2卷,第3期,第8-14页,pISSN 3105-6741、eISSN 3105-675X 发布者:Quest Press 发布日期:2026/11/2
Open Access 浏览160次

 

基层卫生中心高血压合并 2 型糖尿病患者服药依从性现状及影响因素研究


胡俊瑶

成都市新津区安西镇公立卫生院,四川成都,610000

摘要:目的:了解基层卫生中心高血压合并2型糖尿病患者的服药依从性现状,并从社会人口学特征、疾病相关因素、用药方案及社会支持等方面探讨其影响因素,为基层慢性病管理提供循证依据。方法:于2025年6月至2026年3月,采用方便抽样法选取四川省成都市某1家社区卫生服务中心就诊的高血压合并2型糖尿病患者共420例作为研究对象。采用一般资料调查问卷和中文版8条目Morisky服药依从性量表(MMAS-8)进行问卷调查。采用单因素分析及多因素Logistic回归分析筛选服药依从性的影响因素。结果:420例患者服药依从性得分为(5.52±1.12)分,服药依从性高者172例(40.95%)。多因素logistic回归分析显示,年龄≥65岁(OR=0.521,95%CI:0.336~0.807)、日服药种类≥3种(OR=0.358,95%CI:0.228~0.562)、日服药次数≥3次(OR=0.442,95%CI:0.261~0.748)是服药依从性的危险因素,城镇职工医保(OR=2.013,95%CI:1.278~3.171)、接受过用药指导(OR=1.872,95%CI:1.203~2.914)、较高社会支持水平(OR=1.965,95%CI:1.241~3.112)是服药依从性的保护因素(均P<0.05)。结论:基层卫生中心高血压合并2型糖尿病患者服药依从性整体偏低。高龄、日服药种类≥3种、日服药次数≥3次是依从性不佳的主要障碍,而城镇职工医保、接受过用药指导及良好的社会支持可显著提升依从性。基层卫生中心应针对上述因素开展精准化、个体化的干预措施。

关健词:高血压;2 型糖尿病;共病;服药依从性;影响因素
Current status and influencing factors of medication compliance in patients with hypertension and type 2 diabetes mellitus in primary health centers

Junyao Hu

Anxi Town public Health Center,Xinjin district,Chengdu city,610000

Abstract:Objective:To understand the current status of medication compliance in patients with hypertension and type 2 diabetes in primary health centers,and to explore the influencing factors from the aspects of social demographic characteristics,disease-related factors,medication regimens and social support,so as to provide evidence-based basis for chronic disease management in primary health centers.Methods:From June 2025 to March 2026,a total of 420 patients with hypertension and type 2 diabetes in a community health service center in Chengdu City,Sichuan Province were selected as the research objects by convenience sampling method.The general information questionnaire and the Chinese version of the 8-item Morisky Medication Adherence Scale (MMAS-8) were used for the questionnaire survey.Univariate analysis and multivariate Logistic regression analysis were used to screen the influencing factors of medication compliance.Results:The score of medication compliance of 420 patients was (5.52±1.12),and 172 patients (40.95%)had high medication compliance.Multivariate logistic regression analysis showed that age ≥65 years old (OR=0.521,95%CI:0.336-0.807),the types of daily medication ≥3 (OR=0.358,95%CI:0.228-0.562),the frequency of daily medication ≥3 (OR=0.442,P < 0.05),and the frequency of daily medication ≥3 (OR=0.442,P < 0.05)were independent risk factors for adverse events.Urban employee medical insurance (OR=2.013,95%CI:1.278-3.171),receiving medication guidance (OR=1.872,95%CI:1.203-2.914),higher level of social support (OR=1.965,95%CI:1.261-0.748)were risk factors for medication compliance.95%CI:1.241-3.112)were the protective factors of medication compliance (all P<;0.05).Conclusion :The overall medication compliance of patients with hypertension and type 2 diabetes in primary health centers is low.Old age,≥3 kinds of daily medication,and ≥3 times of daily medication were the main barriers to poor compliance,while urban employee medical insurance,medication guidance and good social support could significantly improve compliance.Primary health centers should carry out precise and individualized intervention measures according to the above factors.


Keywords : Hypertension;Type 2 diabetes mellitus;Comorbidity;Medication adherence;Influencing factors


参考文献
[1] 中国高血压防治指南修订委员会.中国高血压防治指南(2018 年修订版)[J].中华心血管病杂志,2019,47(1):24-56.
[2] NCD Risk Factor Collaboration.Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019:a pooled analysis of 1201 population-representative studies with 104 million participants[J].Lancet,2021,398(10304):957-980.
[3] International Diabetes Federation.IDF Diabetes Atlas,10th edn[M].Brussels:IDF,2021.
[4] 国家心血管病中心.中国心血管健康与疾病报告2021[M].北京:科学出版社,2022.
[5] 中华医学会糖尿病学分会.中国 2 型糖尿病防治指南(2020 年版)[J].中华糖尿病杂志,2021,13(1):4-67.
[6] Morisky DE,Ang A,Krousel-Wood M,et al.Predictive validity of a medication adherence measure in an outpatient setting[J].J Clin Hypertens (Greenwich),2008,10(5):348-354.
[7] 陈维尔,邱艳,潘晓华,等.高血压共病糖尿病患者服药依从性调查及影响因素分析[J].中华全科医学,2024,22(4):601-604.
[8] 肖水源.《社会支持评定量表》的理论基础与研究应用[J].临床精神医学杂志,1994,(02):98-100.
[9] Kwakye AO,Kretchy IA,Peprah P,Mensah KB.Factors influencing medication adherence in co-morbid hypertension and diabetes patients:A scoping review. Explor Res Clin Soc Pharm.2024;13:100426.
[10] 孙秋石,杨欣,周玲珠,等.我国基层医疗机构心血管代谢性疾病管理的现实困境与优化路径[J].护理研究,2026,40(13):2210-2215.
[11] 蔡乐,刘传斌,高媛,等.老年慢性病患者用药依从性现状及其影响因素[J].中华老年多器官疾病杂志,2023,22(2):86-90.
[12] Kim SJ,Kwon OD,Han EB,et al.Impact of number of medications and age on adherence to antihypertensive medications : A nationwide population-based study. Medicine (Baltimore).2019;98(49):e17825.
[13] Baah-Nyarkoh E,Alhassan Y,Dwomoh AK,Kretchy IA.Medicated-related burden and adherence in patients with co-morbid type 2 diabetes mellitus and hypertension. Heliyon.2023;9(4):e15448.
[14] 北京高血压防治协会,中国老年学和老年医学学会,北京市社区卫生协会,等.成人高血压合并 2 型糖尿病和血脂异常基层防治中国专家共识(2024 年版)[J].中国全科医学,2024,27(28):3453-3475+3482.
[15] 黄燕杨.健康信念模型干预的标准化认知行为干预对老年慢性病患者遵医行为的影响[J].中国医药指南,2025,23(12):77-80. DOI:10.15912/j.issn.1671-8194. 2025.12.021.
[16] Shen B,Guan T,Du X,Pei C,Zhao J,Liu Y.Medication Adherence and Perceived Social Support of Hypertensive Patients in China:A Community-Based Survey Study.Patient Prefer Adherence.2022 ;16 :1257-1268. [17] Yu J,Chen D,Fu Y,et al.Pathways to self-management among older adults with multimorbidity in rural China:A fuzzy-set qualitative comparative analysis.Int J Nurs Sci.2026;13(2):130-139.
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
版权声明
Copyright Statement
本文采用知识共享“署名 4.0 国际”许可 (CC BY 4.0) 进行许可。许可协议详情请访问: https://creativecommons.org/licenses/by/4.0/。
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). For details of the license, please visit:https://creativecommons.org/licenses/by/4.0/.

 
Peer Review
同行评审
Editorial Services
编辑服务
Research Ethics Policy
研究伦理政策
Contributorship & Authorship
贡献者与署名
Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
关于 Quest Press / Macau Sino-Foreign Medical Publishing Ltd.
Global Indexing
全球索引
Copyright Licensing
版权许可
Data Sharing Policy
数据共享政策
Appeal/Correction/Retraction
申诉/更正/撤回
Online Submission
线上投稿
To the Librarian
致图书馆员
Open Access Statement
开放获取声明
Misconduct Handling Policy
处理不端行为政策
Content Licensing
内容许可
Guidelines for Reviewers
审稿人指南
Quality Control Mechanism
质量把控机制
Academic Misconduct Screening Policy
学术不端筛查政策
Advertising Policy
广告政策
Article Processing Charge (APC)
文章处理费
Publication Ethics Policy
出版伦理政策
Joining the Editorial Board, Associate Editors, Peer Reviewers, and Editor-in-Chief
加入编委、副主编、同行评审专家及主编
Quest Press
Bridging Research to a Global Stage.
academia
© 2025-2026 Macau Sino-Foreign Medical Publishing Ltd.(MSFMP)
Address: Unit D, 7th Floor, No. 19, Rua de Pa̍k-chiông Vai, Macau
Tel: +853 6881 9699 / Email: QuestPress@hotmail.com
The MSFMP publishes articles under the following open access license.
Quest Press
is a member of the following organizations.